{"links":{"html":"https://www.erudio.com/reports/interpath-009-nct06623422","json":"https://www.erudio.com/reports/interpath-009-nct06623422.json","markdown":"https://www.erudio.com/reports/interpath-009-nct06623422.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"interpath-009-06623422"}},"request":"https://www.erudio.com/contact?report=interpath-009-06623422"},"offer":{"cited_commentary_sources":18,"verified_hcp_statements":82,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"interpath-009-nct06623422"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=interpath-009-06623422","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/interpath-009-nct06623422","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T00:34:13.934937Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Disease-Free Survival (DFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":20,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":14,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":1,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":16,"coverage":"discussed","id":"A1","source_count":8,"title":"Melanoma-to-lung translation and standards for lung-specific evidence"},{"claim_count":15,"coverage":"discussed","id":"A2","source_count":5,"title":"Incremental value, sequencing and fair comparisons"},{"claim_count":3,"coverage":"discussed","id":"A3","source_count":1,"title":"MRD-informed escalation in early-stage NSCLC"},{"claim_count":12,"coverage":"discussed","id":"A4","source_count":1,"title":"Individualized manufacturing, turnaround and global delivery"},{"claim_count":11,"coverage":"discussed","id":"A5","source_count":7,"title":"Research access, recruitment, referral and fairness"},{"claim_count":8,"coverage":"discussed","id":"A6","source_count":3,"title":"Personalization and the proposed vaccine–checkpoint mechanism"}],"counts":{"cited_sources":19,"claims_by_expression_type":{"comparison":5,"experience":1,"interpretation":23,"opinion":21,"primary_context":1,"question":7,"restatement":13,"uncertainty":4,"unspecified":7},"claims_by_kind":{"protocol_statement":1,"source_observation":81},"clinician_statements":14,"evidence_units":82,"findings":7,"organisational_accounts":3,"people_cited":10,"people_identity_verified":9,"people_total":12,"screened_sources":46,"verified_claims":82},"findings_index":[{"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":4,"views":3},"has_counterview":true,"limitations":6,"links":{"context":3,"support":11},"ma_question":true,"named_voices":5,"passages":7,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Melanoma provides encouragement, but prior IO exposure and residual disease make lung-specific benefit an open question"},{"id":"F2","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":4,"restated":1,"views":3},"has_counterview":true,"limitations":3,"links":{"context":5,"support":9},"ma_question":true,"named_voices":5,"passages":10,"sources":3,"sources_by_kind":{"commentary":3}},"title":"The central controversy is incremental value: an alternative to neoadjuvant IO, or a treatment after it?"},{"id":"F3","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":3,"views":9},"has_counterview":true,"limitations":3,"links":{"context":6,"support":15},"ma_question":true,"named_voices":0,"passages":17,"sources":1,"sources_by_kind":{"media":1}},"title":"Safety reassurance is vaccine-specific and largely melanoma-based; systemic checkpoint toxicity remains a separate concern"},{"id":"F4","structure":{"claims":23,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":4,"views":17},"has_counterview":false,"limitations":4,"links":{"context":1,"support":25},"ma_question":true,"named_voices":2,"passages":24,"sources":5,"sources_by_kind":{"commentary":2,"media":2,"registry":1}},"title":"Non-pCR enrichment is framed as a high-need immune-rescue experiment, sometimes with stronger biological conclusions than the evidence establishes"},{"id":"F5","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":0},"has_counterview":false,"limitations":4,"links":{"context":1,"support":3},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"MRD-based escalation adds a related selection question without establishing who benefits from the vaccine"},{"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":4,"views":6},"has_counterview":false,"limitations":3,"links":{"context":3,"support":14},"ma_question":true,"named_voices":0,"passages":9,"sources":1,"sources_by_kind":{"media":1}},"title":"Manufacturing speed, consistency and geography are presented as conditions for practical access"},{"id":"F7","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":4,"views":8},"has_counterview":false,"limitations":4,"links":{"context":2,"support":13},"ma_question":true,"named_voices":5,"passages":12,"sources":8,"sources_by_kind":{"commentary":5,"media":3}},"title":"Enthusiasm is directed toward research enrollment and awareness, not routine-care availability"}],"medical_affairs_question":"What evidence would establish incremental postoperative value after prior chemo-immunotherapy while distinguishing vaccine tolerability, checkpoint toxicity and feasible research access?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Translation after prior IO remains the decisive efficacy question"},{"id":"section-2","level":2,"title":"2. Sequencing changes the meaning of the comparator debate"},{"id":"section-3","level":2,"title":"3. Separate vaccine reactogenicity from systemic immune-mediated harm"},{"id":"section-4","level":2,"title":"4. Non-pCR selection supports a specific rationale, not a proven resistance mechanism"},{"id":"section-5","level":2,"title":"5. MRD raises a related escalation question, not a vaccine-selection rule"},{"id":"section-6","level":2,"title":"6. A timely individual product is different from scalable global access"},{"id":"section-7","level":2,"title":"7. Recruitment enthusiasm needs eligibility and randomization alongside it"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F4","shared_claims":2}],"id":"T1","label":"Primary endpoint: Disease-Free Survival (DFS)"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F4","shared_claims":13},{"id":"F7","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F3","shared_claims":14}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F7","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T00:34:13.934937Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T00:44:51Z","record_hash":"d0971788f3b0de685138e650934bae379bf6eb9c42f20f0880c86c512fc556ed","release_hash":"f3f2079f0e45bbee7431195032a22622d5b21b5d9ca111e781bef9ef74c941f6","report_id":"erudio-nct06623422","run_id":"9f3af278-807c-4273-9d6c-3b661d613fa4","schema_version":"5.0","slug":"interpath-009-06623422","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"INTerpath-009 asks whether adding intismeran autogene to postoperative pembrolizumab prolongs disease-free survival in patients with resected non-small-cell lung cancer and residual disease after neoadjuvant chemo-immunotherapy. Commentary comes from X and Bluesky posts, a podcast and YouTube videos. Debate centers on whether melanoma findings translate to lung cancer and whether vaccination adds benefit after neoadjuvant immunotherapy. Enthusiasm focuses on research enrollment, not routine-care availability.","meta_description":"46 sources screened · 82 verified statements (14 from clinicians verified by NPI or staff page) from 19 sources · 7 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-3ba7864bea0b5644e854","claim-d8c71088bee0465b40c7"],"id":"F2","paraphrase":"An X post asks which treatment comparison would assess the vaccine’s contribution and whether INTerpath-009 addresses that question.","source_channel":"x_thread","source_date":"2026-10-23","title":"The central controversy is incremental value: an alternative to neoadjuvant IO, or a treatment after it?"},{"cited_claim_ids":["claim-7a3b387c87107f794c0f","claim-7e0e04903ee0949a5781"],"id":"F4","paraphrase":"A podcast discussion asks why INTerpath-009 enrolls patients with residual tumor after preoperative treatment.","source_channel":"podcast","source_date":"2026-09-09","title":"Non-pCR enrichment is framed as a high-need immune-rescue experiment, sometimes with stronger biological conclusions than the evidence establishes"}]},"publication":{"approved_at":"2026-10-31T00:44:51Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-31T02:18:23Z","summary":"Corrected to match the delivered report: the limitations; the sample findings; the report description."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":46},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","60 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","This report describes the sources reviewed for this edition, not all HCP views or their prevalence; source and repost counts must not be read as independent clinician counts.","No INTerpath-009 efficacy or safety result is provided in the statements. Melanoma efficacy references and KEYNOTE-942 safety figures cannot establish benefit or safety in the target NSCLC population.","A full protocol and an exact-trial results publication were not available for this report, and only part of the intervention-related regulatory material was reviewed.","Some surrounding discussion of perioperative and neoadjuvant evidence in resectable NSCLC, biomarker testing, specialist capacity and equitable access is not fully represented. This limits the account of the clinical and implementation rationale accompanying cross-study questions.","Surrounding melanoma discussion of patient suitability, neoadjuvant feasibility, manufacturing attrition, generalisability, neoantigen validation, control selection and unresolved overall survival is also incomplete; the report should not be read as a complete appraisal of those melanoma studies.","Speakers in the podcast and short videos are unnamed. Publisher names, account identities and professional profiles do not establish who spoke those passages.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Post dates locate the commentary, not a session or readout. Apart from the explicit clarification within the a speaker–another speaker exchange, dates do not establish changes of mind.","Mechanistic, manufacturing and commercial-viability assertions remain attributed views; no comparative evidence is supplied to validate immune-rescue explanations, manufacturing uniformity or broad equitable access.","No specific interpretation of the listed secondary endpoints was identified in the material reviewed; this does not establish that such discussion does not exist elsewhere.","Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, capacity, and access barriers in resectable lung cancer.","Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, specialist-capacity and equitable-access barriers in resectable NSCLC."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":14,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":18,"methods":1},"count":19,"evidence_window":{"end":"2026-10-25","start":"2024-10-28"},"retrieval_snapshot":"2026-10-30T23:33:33.222203Z","timeline":[{"count":1,"week":"2024-W44"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2026-W13"},{"count":2,"week":"2026-W29"},{"count":6,"week":"2026-W34"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W39"},{"count":4,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06623422:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06623422:context","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:508496cb-3441-46b3-a4fe-e0d440e6adc6:20260624","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2lrdv6x4jejmm4sisg4zti4a-3my36emkj5s2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6vwezbhj7wwowu4sbur5npjk-3mgxbhlzqwc2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-oyncnox7oot7cd6scxhh2udd-3mtcw6dctec2g","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c0cc6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1850858722312007915:0dbcad3d-e4a2-487f-b841-c2077e386442","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1850910558150615080:3310fe4d-7ddf-4d98-9027-7a3bb5f02051","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1850946488211226988:867fc194-daa4-4e17-a53b-14261c6a3221","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1851656004045279435:b9b4fd87-ca82-4c27-96f3-a3b7067d451b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1853793649248592379:522a8d24-6ecf-471d-8e6f-5af2c53991c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1864307073757876646:89b1dfc7-9ed4-400b-9f94-bcf92c64a4ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1874612577398923461:e5363558-93dc-4679-ae5c-ae2ab068411e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1878833167399842223:8c8b0cf0-c1c6-4d60-b43a-b1f95d9edfe5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1890917010843832328:7d8e9f59-21f0-496b-b7fb-d49192d3dd0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915765140320133240:bc48db87-b0cb-469b-9898-1685f7e7791e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1916151979421663743:12e39511-e94d-4869-8961-95fab640adb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1948460812185862327:e14795bf-fa60-40eb-882d-697945f6e4b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974492644018475504:cfbede50-432a-4f87-82b4-a13759d23904","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032484727593279753:a2cad7f0-0470-4978-9746-3baf9aa4603c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037479465995944096:26ce6886-7c05-4b11-9800-ed787a5e2c28","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037801698480001345:5f3071e9-8937-46a7-9502-39431fc6bc95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058914935862948270:531c8003-ffe2-46c1-bbc4-486bbc3ab2aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061493904487354557:078a5b56-50fa-42f3-abc0-5616deb8dfd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061568663317082252:f1396ed2-3770-44a1-9877-51c3f994e884","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2076761224805564443:d9cceb43-9c82-463e-a91f-cabc7b27733a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089410713190031705:8a5c2f1b-8d79-4b23-b25a-35b5f81edf7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089503635591864637:85388f86-3fdb-416d-a735-96d1ad670d97","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090041549514027238:813df8c9-b6a5-49ce-922b-b72ec593df88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090069927843533123:0714b4af-7744-4ecb-88f6-4b82b8882124","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090070108387360827:1900b827-437d-4823-a72c-77015c62c99a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090174229475958911:97b94d07-1a38-4166-8fc9-c29cb476f69c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090190664713539647:85430323-d4a9-4462-bae0-001ce4cd1014","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090332612376056298:a799dea1-33d5-4f9d-8afb-12ede2101c70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090335942787911870:4bc67f8f-d8ba-42cc-835f-0551396fd933","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098056908447912218:e1098711-3668-479d-94a0-cc2af60dfd63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102971158895399207:ca84bc0c-ac62-4e5e-ac07-9ab570b042cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113312418365366451:77251f6e-fa30-4a1d-9d74-ee15a3198c93","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113392319944876112:c62ea3b1-2921-463b-b34c-1d1816e811a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113407927478309269:5870ac0e-25a0-4f0c-8f7f-7ae32160868e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113540748184293805:2b2a21df-492b-46cf-bad5-937b92967a87","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113619447730909413:0a863598-29ab-4d32-ac66-29a8053feb18","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113660230290587807:a9a90b3c-77eb-4fa3-8e12-f7ce25c079d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114009405285167210:90891137-9793-492b-97aa-bd395fbaaf5b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114071534696616364:47909d50-2d7c-436e-b80b-c07038e4d863","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114247184350880040:ec98a554-ae05-4d73-9d14-8f00da538b98","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Lwh48OPHia0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:m2qnr30m1Qg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":40,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":46},"count":46,"evidence_window":{"end":"2026-10-25","start":"2024-10-28"},"retrieval_snapshot":"2026-10-30T23:33:33.231786Z","timeline":[{"count":4,"week":"2024-W44"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W49"},{"count":1,"week":"2025-W01"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W07"},{"count":2,"week":"2025-W17"},{"count":1,"week":"2025-W30"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W40"},{"count":2,"week":"2026-W11"},{"count":1,"week":"2026-W12"},{"count":2,"week":"2026-W13"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":2,"week":"2026-W29"},{"count":11,"week":"2026-W34"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W42"},{"count":9,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"reason":"Unmapped registry intervention: intismeran autogene","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"INTerpath-009","aliases":["INTerpath-009","V940-009/INTerpath-009","A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)"],"brief_title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","collaborators":["ModernaTX, Inc."],"conditions":["Carcinoma, Non-Small-Cell Lung"],"display_condition":"resectable stage II–IIIB (N2) NSCLC not achieving pCR","display_interventions":[["intismeran autogene (V940)","pembrolizumab"]],"enrollment":{"count":680,"type":"ESTIMATED"},"interventions":[{"name":"Pembrolizumab","synonyms":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Cisplatin","synonyms":["Platinol®","Platinol®-AQ"],"type":"DRUG"},{"name":"Carboplatin","synonyms":["Paraplatin®"],"type":"DRUG"},{"name":"Pemetrexed","synonyms":["Alimta®"],"type":"DRUG"},{"name":"Gemcitabine","synonyms":["Gemzar"],"type":"DRUG"},{"name":"Paclitaxel","synonyms":["Taxol®","Onxol®"],"type":"DRUG"},{"name":"Intismeran autogene","synonyms":["mRNA-4157","V940"],"type":"BIOLOGICAL"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"OTHER"}],"nct_id":"NCT06623422","official_title":"A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2033-05-16","type":"ESTIMATED"},"primary_endpoints":[{"description":"DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause, whichever occurs first.","measure":"Disease-Free Survival (DFS)","timeFrame":"Up to ~97 months"}],"registered_date":{"date":"2024-10-02","type":"ACTUAL"},"registry_last_updated":"2026-10-30","registry_url":"https://clinicaltrials.gov/study/NCT06623422","short_name":"INTerpath-009","short_name_basis":"canonical_name","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2024-10-21","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"V940-009","type":"sponsor_study_id"},{"domain":"EU CT","id":"2023-506327-29-00","type":"registry"},{"domain":"UTN","id":"U1111-1293-5814","type":"registry"},{"domain":"MSD","id":"INTerpath-009","type":"other"},{"domain":"jRCT","id":"jRCT2061240105","type":"registry"}],"study_type":"INTERVENTIONAL"}}}